People On The Move: HRA Pharma, Hofseth BioCare, UK CHM
A round-up of the latest people moves in Europe's health and wellness markets: HRA Pharma's CEO David Wright steps down; Hofseth BioCare promotes Ødegård to lead the company; and the UK's Commission on Human Medicines appoints nine new members.
You may also be interested in...
HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.
Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.